A phase II study of Gleevac [imatinib] in patients with recurrent platinum-resistant, taxane-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Trial Profile

A phase II study of Gleevac [imatinib] in patients with recurrent platinum-resistant, taxane-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2012

At a glance

  • Drugs Imatinib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Mar 2012 Actual patients number is 73 as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top